Pulmonology

The importance of AT2 cells in repairing injured alveoli and maintaining alveoli number and lumen size suggests that COPD therapies may be implemented to improve AT2 cell biology and/or increase AT2 cell numbers.

Abebaw Yohannes, MSc, PhD, speaks about his team’s pilot study designed to assess the use of duloxetine for patients with COPD and comorbid depression.

Pilot study tests duloxetine’s feasibility for depression in COPD, examining patient/physician attitudes, treatment barriers, and therapy effects.

The RECEIVE study develops tools to standardize returning chest CT results in the Lung Health Cohort, improving engagement and ethical practices.

Medicare has selected 15 additional drugs to negotiate prices directly with participating drug companies, including semaglutide (Ozempic).

Current asthma diagnosis requires specialized breathing tests that can be challenging for young children.

A study shows the causal link between apoA-I and chronic obstructive pulmonary disease, showing lipid metabolism's role in the pathogenesis of COPD.

Within 2 years of death, fall-risk increasing drug burden was associated with greater odds of an injurious fall.

These findings on asthma healthcare utilization resulted from the lack of a winter peak in RSV during the first months of the COVID-19 pandemic.

To celebrate the close of 2024, we're recapping the 10 most popular approval articles across the HCPLive Network of brands.

Lungcast reflects on this year in pulmonology, looking back at such topics ranging from the American Lung Association ‘State of the Air’ report to artificial intelligence in lung imaging.

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.

In this month's episode of Lungcast, Jacob Sands, MD, discusses the American Lung Association’s recently newly-released 2024 State of Lung Cancer report.

This portion of the latest Lungcast episode includes a discussion of therapies, triggers, and management of AERD.

During his interview, Criner discusses several notable updates to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report regarding COPD care.

In this segment of the latest Lungcast episode, the characteristics of AERD and the concerns of patients were highlighted.

This segment of Han’s interview featured a discussion of the safety profile of dupilumab and ensifentrine, as well as other details in the GOLD 2025 Report.

In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.

In these updates and new sections, the 2025 GOLD report included highlighted climate change, cardiovascular risk, and pulmonary hypertension.

A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.

In the most recent Lungcast, Rachel Eddy, PhD, joined host Al Rizzo, MD, to speak to listeners about the current and future uses of AI in lung imaging.

Patients who underwent FESS required less medication and had fewer allergy and pulmonology visits than patients who did not have surgery.

Proof-of-mechanism data from the phase 1b/2a study of WVE-006 represent the first-ever clinical demonstration of RNA editing in humans.

The literature review suggests allergen immunotherapy can effectively treat allergic asthma and prevent its development in patients with allergic rhinitis.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.